Seeking Alpha
15 Jan 2026, 15:24 UTC · 38w ago
Verdict
Source says Upgrade. We score TGTX +1.00 across three claims.
Score confirms the headline.
Upgrade
Rating stated in the headline
+1.00strongly bullish
More positive than 99% of ticker scores this week
Search tags
What the story claims
3 claims · scored −1 bearish … +1 bullish
TG Therapeutics guides 2026 BRIUMVI U.S. net revenue of $825–$850 million, implying ~40% year-over-year growth.
So whatHigh-growth revenue guidance is a primary driver for valuation and suggests strong commercial execution.
More positive than 99% of claims this week
The company is upgrading its rating from Hold to Strong Buy based on accelerating market share gains in the Multiple Sclerosis market.
So whatA Strong Buy upgrade from a financial analyst typically triggers immediate positive sentiment and buying pressure.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
More positive than 93% of claims this week
TGTX is developing a subcutaneous formulation and leveraging low pricing to position itself for future margin expansion.
More positive than 79% of claims this week
Which stocks this story touches
More positive than 99% of ticker scores this week
The company received a rating upgrade to Strong Buy due to accelerating revenue growth and positive guidance for its drug BRIUMVI.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
7h ago
+86.1%
Price agrees with the score
$54.98 vs $29.54 close before publication (Jan 14) · not market-adjusted
TGTX chart →
